Cure My Disease

Don't miss your cure!

 Log in / Sign up

Botox for stroke recovery: a tiny trial tests whether it can unlock a paralyzed arm

NCT ID NCT03453008

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

Many stroke survivors are left with a stiff, hard-to-move arm due to spastic cocontractions—muscles that contract at the wrong time. This small study tests whether injecting botulinum toxin A into the elbow flexor muscles can reduce those cocontractions and improve active arm movement. Fourteen participants will be evaluated before and after their usual injection to see if the treatment helps restore a functional grip.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
botulinum toxin A injected into elbow flexor muscles
What this could lead to
If successful, this could point toward a better way to restore functional grip in stroke survivors with residual arm weakness.
What could go wrong
This is a very small, early-stage study with only 14 participants, so results may not apply broadly. Botulinum toxin injections carry risks of muscle weakness or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14 people

The number who actually took part.

Started

Jan 2018

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with Ischemic or hemorrhagic stroke of more than 6 months, cortical and / or subcortical and an who can have a Botulinum Toxin A injection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Having notified his non-opposition to participate in the search * Ischemic or hemorrhagic stroke of more than 6 months, cortical and / or subcortical; * Indication to the realization of an injection of Botulinum Toxin A in the flexor muscles of the elbow according to the usual clinical criteria: presence of a functional complaint or aesthetic expressed by the patient and related to hyperactivity muscular (spasticity or cocontraction) on the flexor muscles elbow, which is a focal treatment by injection of botulinum toxin; * Possibility of active extension of elbow\> 20 °; * Patients naive to Botulinum Toxin A or more than 4 months of a first injection of Botulinum Toxin A, having targeted the elbow flexors. Exclusion Criteria: * Passive limitation of elbow extension\> 30 °; * Pain when performing active movements of flexion / extension of the elbow * Cognitive impairment limiting the comprehension of three basic instructions (proof test of the 3 papers of the MMS); * Evolutionary or decompensated neurological pathology; Ischemic or haemorrhagic stroke of less than 6 months; * General contraindication to the production of botulinum toxin; history of myasthenia gravis, Lambert Eaton syndrome; history of neuromuscular disease; surgery with curarization for less than 1 month; treatment with aminoglycoside, aminoquinoline or cyclosporine * Legal incapacity (safeguard of justice, guardianship).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular accident are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular accident Stroke

Contacts and locations

Locations

  • University Hospital Toulouse

    Toulouse, 31052, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.